Sensus Healthcare 将来の成長
Future 基準チェック /16
Sensus Healthcareは、77.3%と19.9%でそれぞれ年率77.3%で利益と収益が成長すると予測される一方、EPSはgrowで78%年率。
主要情報
77.3%
収益成長率
77.97%
EPS成長率
| Medical Equipment 収益成長 | 16.4% |
| 収益成長率 | 19.9% |
| 将来の株主資本利益率 | n/a |
| アナリストカバレッジ | Low |
| 最終更新日 | 09 Jul 2026 |
今後の成長に関する最新情報
Recent updates
ナラティブ更新 • Jul 06
SRTS: 2026 Reimbursement Shift Will Drive Upside Despite Softer Assumptions
Analysts have reduced their price target on Sensus Healthcare by $1, citing slightly softer assumptions for fair value, revenue growth, profit margins, and a higher future P/E multiple in their updated models. What's in the News Sensus Healthcare reported that from January 1, 2026 to March 31, 2026, it repurchased 0 shares for US$0 million under its existing share buyback program.
ナラティブ更新 • Jun 22
SRTS: Future Upside Will Hinge On 2026 Margin Recovery
Analysts have trimmed their price target on Sensus Healthcare by $1 to $5.75, citing updated assumptions on long term profit margin and a lower future P/E multiple. What’s in the News for Sensus Healthcare Sensus Healthcare reported that from January 1, 2026 to March 31, 2026, the company repurchased 0 shares under its existing buyback program.
ナラティブ更新 • Jun 04
SRTS: 2026 Reimbursement Codes Will Support Long Term Earnings Potential
Analysts have reduced their price target on Sensus Healthcare by $1 to $6, reflecting a lower fair value estimate and sharply reduced profit margin assumptions, partly offset by expectations for continued revenue growth from the SRT platform, supported by new reimbursement codes planned for 2026. Analyst Commentary Recent research points to a more cautious tone around Sensus Healthcare, with the trimmed price target reflecting reduced profit margin assumptions, even as analysts still factor in potential revenue contribution from the SRT platform and future reimbursement changes planned for 2026.ナラティブ更新 • May 19
SRTS: Future Returns Will Hinge On 2026 Reimbursement Code Reset
Analysts have trimmed their price target on Sensus Healthcare from $6.88 to $5.75, citing revised fair value assumptions that factor in updated expectations for revenue growth, profit margins and a much higher future P/E multiple linked to anticipated demand for the SRT platform and new 2026 reimbursement codes. Analyst Commentary Recent research highlights both optimism and caution around Sensus Healthcare as analysts recalibrate their expectations and fair value work.ナラティブ更新 • Apr 25
SRTS: 2026 Reimbursement Codes And New Platform Rollout Will Drive Upside
Narrative Update Overview Analysts have trimmed their average price target on Sensus Healthcare from $8.00 to $7.50, reflecting mixed views that balance expectations for stronger SRT platform revenue supported by new 2026 reimbursement codes, alongside the impact of recent quarterly results that fell short due to no sales from a key customer. Analyst Commentary Bullish analysts remain constructive on Sensus Healthcare, pointing to the company’s SRT platform and upcoming reimbursement changes as key elements that could support long term growth.ナラティブ更新 • Apr 10
SRTS: 2026 Reimbursement Shift Will Support Future Skin Therapy Adoption
Analysts have updated the price target range for Sensus Healthcare. One analyst raised the target to $7.50, citing expectations for SRT platform revenue supported by new 2026 reimbursement codes.ナラティブ更新 • Mar 27
SRTS: Reimbursement Shift In 2026 Will Drive Future Upside Potential
Narrative Update: Sensus Healthcare (SRTS) The blended analyst price target for Sensus Healthcare has shifted from $8 to $7.50. Analysts are balancing expectations for very strong SRT platform revenue in 2026, tied to new reimbursement codes, with the impact of Q4 results that missed forecasts due to no sales from the company’s largest customer.ナラティブ更新 • Mar 10
SRTS: Future Upside Will Depend On 2026 Reimbursement Code Changes
Analysts have nudged their fair value estimate for Sensus Healthcare slightly higher to $6.88, reflecting mixed recent research in which one firm trimmed its price target to $6 after weak Q4 results, while another initiated coverage with a more upbeat $7.50 target tied to expectations for the SRT platform and 2026 reimbursement changes. Analyst Commentary Bullish Takeaways Bullish analysts point to the SRT-100/Vision platform as the core driver of the current fair value view, given its focus on treating both oncological and non-oncological skin conditions, which supports their more constructive stance on long term growth potential.ナラティブ更新 • Feb 24
SRTS: Future Upside Will Hinge On Reducing Largest Customer Concentration Risk
Narrative Update on Sensus Healthcare Analysts have trimmed their price target on Sensus Healthcare to $6 from $8, pointing to Q4 results that came in well below their expectations after the company reported no sales from its largest customer. Analyst Commentary Analysts are adjusting their views on Sensus Healthcare after the latest Q4 report, with the lower price target reflecting both execution concerns and how the market may now be valuing the shares.分析記事 • Feb 15
Sensus Healthcare, Inc. (NASDAQ:SRTS) Just Reported And Analysts Have Been Cutting Their Estimates
As you might know, Sensus Healthcare, Inc. ( NASDAQ:SRTS ) last week released its latest annual, and things did not...ナラティブ更新 • Feb 10
SRTS: Auditor Transition And Margin Outlook Will Support Future Upside
Analysts have reduced their price target on Sensus Healthcare to US$20.65 from US$21.29, reflecting updated assumptions that include slightly higher projected revenue growth, a modestly stronger profit margin profile, and a marginally lower future P/E multiple. What's in the News Auditor change: Sensus Healthcare's Audit Committee dismissed Berkowitz Pollack Brant Advisors + CPAs, LLP and approved Carr, Riggs & Ingram, LLC as the new independent registered public accounting firm following CRI's acquisition of certain BPB capital markets assets, effective January 1, 2026 (Key Developments).ナラティブ更新 • Jan 25
SRTS: Slightly Improved Outlook And Auditor Transition Will Support Future Upside
Analysts have raised their price target on Sensus Healthcare by a small amount, citing slightly higher assumptions for revenue growth and profit margins, along with a modestly lower discount rate and a marginally reduced future P/E multiple. What's in the News The Audit Committee of Sensus Healthcare's Board of Directors dismissed Berkowitz Pollack Brant Advisors + CPAs, LLP as the independent registered public accounting firm and approved Carr, Riggs & Ingram, LLC as the new auditor, following CRI's acquisition of certain capital markets assets from BPB effective January 1, 2026 (company filing).分析記事 • Jan 14
Sensus Healthcare, Inc.'s (NASDAQ:SRTS) Share Price Boosted 38% But Its Business Prospects Need A Lift Too
Despite an already strong run, Sensus Healthcare, Inc. ( NASDAQ:SRTS ) shares have been powering on, with a gain of 38...ナラティブ更新 • Jan 10
SRTS: Keloid Treatment Breakthrough Will Support Stronger Prospects Despite Trimmed Outlook
Narrative Update on Sensus Healthcare Analysts have modestly raised their price target on Sensus Healthcare, citing slightly adjusted assumptions for discount rate, revenue growth, profit margin and future P/E. Together, these adjustments support a higher fair value estimate now framed at US$8.00.ナラティブ更新 • Dec 26
SRTS: Keloid Treatment Breakthrough Will Drive Stronger Prospects Despite Trimmed Outlook
Analysts have modestly lifted their price target on Sensus Healthcare to reflect slightly faster expected revenue growth and improving profit margins, even as they temper future valuation multiples. Valuation Changes Discount Rate has risen slightly from 7.69% to 7.70%, reflecting a marginally higher required return.ナラティブ更新 • Dec 12
SRTS: Keloid Treatment Breakthrough Will Drive Stronger Prospects Despite Trimmed Outlook
Analysts have trimmed their price target on Sensus Healthcare to approximately 8 dollars from about 10 dollars, citing softer expected revenue growth, lower projected profit margins, and a higher assumed future price to earnings multiple that together point to a more conservative valuation outlook. What's in the News Peer reviewed data from a single center retrospective study in Dermatologic Therapy show that Sensus Healthcare's superficial radiotherapy technology combined with punch excision significantly improved keloid outcomes over one year, including reductions in pain, itching, thickness and irregularity of scars, with no severe adverse reactions reported (study in Dermatologic Therapy).分析記事 • Nov 19
Sensus Healthcare, Inc. (NASDAQ:SRTS) Stock Rockets 26% But Many Are Still Ignoring The Company
The Sensus Healthcare, Inc. ( NASDAQ:SRTS ) share price has done very well over the last month, posting an excellent...分析記事 • Oct 04
Insufficient Growth At Sensus Healthcare, Inc. (NASDAQ:SRTS) Hampers Share Price
You may think that with a price-to-sales (or "P/S") ratio of 1.5x Sensus Healthcare, Inc. ( NASDAQ:SRTS ) is a stock...ナラティブ更新 • Sep 04
Increased CMS Reimbursement And International Expansion Will Unlock Demand
With no new analyst reasoning provided and both the discount rate and future P/E ratio remaining stable, the consensus fair value for Sensus Healthcare is unchanged at $8.00. What's in the News Sensus Healthcare's entire superficial radiation therapy (SRT) system portfolio received Medical Device Single Audit Program (MDSAP) certification.分析記事 • Jul 12
Returns On Capital Are Showing Encouraging Signs At Sensus Healthcare (NASDAQ:SRTS)
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Typically...分析記事 • May 06
Why Sensus Healthcare, Inc. (NASDAQ:SRTS) Could Be Worth Watching
While Sensus Healthcare, Inc. ( NASDAQ:SRTS ) might not have the largest market cap around , it received a lot of...分析記事 • Mar 13
Investors Shouldn't Be Too Comfortable With Sensus Healthcare's (NASDAQ:SRTS) Earnings
Despite posting some strong earnings, the market for Sensus Healthcare, Inc.'s ( NASDAQ:SRTS ) stock hasn't moved much...分析記事 • Feb 25
Sensus Healthcare, Inc. (NASDAQ:SRTS) Stock's 27% Dive Might Signal An Opportunity But It Requires Some Scrutiny
To the annoyance of some shareholders, Sensus Healthcare, Inc. ( NASDAQ:SRTS ) shares are down a considerable 27% in...分析記事 • Feb 08
Revenue Beat: Sensus Healthcare, Inc. Beat Analyst Estimates By 5.6%
Shareholders in Sensus Healthcare, Inc. ( NASDAQ:SRTS ) had a terrible week, as shares crashed 29% to US$5.84 in the...新しいナラティブ • Jan 07
SRTS Market Outlook
Sensus Healthcare (NASDAQ: SRTS) operates in the Healthcare sector and is part of the Medical Devices industry. Specifically, it focuses on the development and commercialization of non-invasive Superf分析記事 • Dec 18
We Think Sensus Healthcare (NASDAQ:SRTS) Might Have The DNA Of A Multi-Bagger
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...分析記事 • Nov 19
Results: Sensus Healthcare, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Shareholders of Sensus Healthcare, Inc. ( NASDAQ:SRTS ) will be pleased this week, given that the stock price is up 19...分析記事 • Nov 12
Sensus Healthcare, Inc. (NASDAQ:SRTS) Doing What It Can To Lift Shares
It's not a stretch to say that Sensus Healthcare, Inc.'s ( NASDAQ:SRTS ) price-to-earnings (or "P/E") ratio of 17.4x...分析記事 • Oct 03
At US$6.10, Is It Time To Put Sensus Healthcare, Inc. (NASDAQ:SRTS) On Your Watch List?
While Sensus Healthcare, Inc. ( NASDAQ:SRTS ) might not have the largest market cap around , it saw a significant share...
新しいナラティブ • Sep 28
Fair Deal Agreement And Global Expansion Set To Revolutionize Revenue And Margins
Strategic shift towards recurring revenue with the Fair Deal Agreement model indicates potential for significant revenue growth from 2025.分析記事 • May 12
Returns At Sensus Healthcare (NASDAQ:SRTS) Are On The Way Up
To find a multi-bagger stock, what are the underlying trends we should look for in a business? One common approach is...分析記事 • Apr 16
Potential Upside For Sensus Healthcare, Inc. (NASDAQ:SRTS) Not Without Risk
With a price-to-sales (or "P/S") ratio of 2.1x Sensus Healthcare, Inc. ( NASDAQ:SRTS ) may be sending bullish signals...分析記事 • Feb 11
Sensus Healthcare, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
The investors in Sensus Healthcare, Inc. 's ( NASDAQ:SRTS ) will be rubbing their hands together with glee today, after...業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2028 | 37 | 1 | N/A | N/A | 2 |
| 12/31/2027 | 30 | -2 | N/A | N/A | 3 |
| 12/31/2026 | 21 | -7 | N/A | N/A | 3 |
| 3/31/2026 | 23 | -8 | -1 | -1 | N/A |
| 12/31/2025 | 27 | -8 | 0 | 1 | N/A |
| 9/30/2025 | 36 | -3 | 2 | 2 | N/A |
| 6/30/2025 | 38 | -1 | 3 | 4 | N/A |
| 3/31/2025 | 39 | 2 | 5 | 5 | N/A |
| 12/31/2024 | 42 | 7 | -1 | -1 | N/A |
| 9/30/2024 | 41 | 9 | 2 | 3 | N/A |
| 6/30/2024 | 36 | 7 | -1 | -1 | N/A |
| 3/31/2024 | 32 | 5 | -5 | -4 | N/A |
| 12/31/2023 | 24 | 0 | -2 | -2 | N/A |
| 9/30/2023 | 25 | -1 | -15 | -15 | N/A |
| 6/30/2023 | 30 | 2 | -12 | -12 | N/A |
| 3/31/2023 | 38 | 6 | -11 | -10 | N/A |
| 12/31/2022 | 45 | 24 | -2 | -1 | N/A |
| 9/30/2022 | 44 | 27 | 7 | 7 | N/A |
| 6/30/2022 | 41 | 25 | 4 | 4 | N/A |
| 3/31/2022 | 34 | 21 | 4 | 4 | N/A |
| 12/31/2021 | 27 | 4 | 0 | 0 | N/A |
| 9/30/2021 | 19 | 0 | 1 | 1 | N/A |
| 6/30/2021 | 15 | -2 | -3 | -3 | N/A |
| 3/31/2021 | 11 | -4 | -2 | -2 | N/A |
| 12/31/2020 | 10 | -7 | -1 | 0 | N/A |
| 9/30/2020 | 13 | -7 | 0 | 0 | N/A |
| 6/30/2020 | 17 | -6 | 1 | 1 | N/A |
| 3/31/2020 | 24 | -3 | 5 | 5 | N/A |
| 12/31/2019 | 27 | -2 | N/A | -2 | N/A |
| 9/30/2019 | 27 | -3 | N/A | -4 | N/A |
| 6/30/2019 | 27 | -2 | N/A | -5 | N/A |
| 3/31/2019 | 26 | -3 | N/A | -12 | N/A |
| 12/31/2018 | 26 | -2 | N/A | -9 | N/A |
| 9/30/2018 | 25 | -3 | N/A | -6 | N/A |
| 6/30/2018 | 23 | -3 | N/A | -5 | N/A |
| 3/31/2018 | 22 | -3 | N/A | -4 | N/A |
| 12/31/2017 | 21 | -4 | N/A | -3 | N/A |
| 9/30/2017 | 19 | -3 | N/A | -2 | N/A |
| 6/30/2017 | 18 | -2 | N/A | -3 | N/A |
| 3/31/2017 | 16 | -2 | N/A | -3 | N/A |
| 12/31/2016 | 15 | 0 | N/A | -1 | N/A |
| 9/30/2016 | 14 | 0 | N/A | -2 | N/A |
| 6/30/2016 | 13 | 0 | N/A | -1 | N/A |
| 3/31/2016 | 11 | 0 | N/A | -1 | N/A |
| 12/31/2015 | 10 | -1 | N/A | -1 | N/A |
| 9/30/2015 | 8 | -2 | N/A | -1 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: SRTS今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: SRTS今後 3 年間、利益が出ない状態が続くと予測されています。
高成長収益: SRTS今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: SRTSの収益 ( 19.9% ) US市場 ( 13% ) よりも速いペースで成長すると予測されています。
高い収益成長: SRTSの収益 ( 19.9% ) 20%よりも低い成長が予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: SRTSの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/13 08:41 |
| 終値 | 2026/07/10 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Sensus Healthcare, Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8
| アナリスト | 機関 |
|---|---|
| Scott Henry | Alliance Global Partners |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Alexander Nowak | Craig-Hallum Capital Group LLC |